Blueprint Care — the flagship
Your decision report, executed by a dedicated clinical team.
Blueprint Care is OnKommon's flagship. It takes the complete molecular picture of your cancer and turns it into a ranked, sign-out-ready treatment plan — then puts a named clinical team beside you to help you act on it, monitor it, and adjust as things change.
It is fed by one of our Signature molecular tests, or by your existing data through Decipher. What you receive is not a variant list. It is the decision — with the reasoning, the alternatives, the access routes, and the human support to carry it out.
Explore the QuestionsA sequencing report tells you what mutations are present. Blueprint Care answers what to do about them.
Of all the options, which treatment should come first — and how confident is that call?
Which drugs are ruled out by this tumour’s biology, so you are not given something futile?
Which clinical trials match this exact profile, and which are recruiting?
Are there biosimilars or assistance programmes that make the plan affordable?
If the first line fails, what is the fallback — and how will we know early?
Is there a hereditary signal that means my family should be tested?
Every Blueprint Care report works through the same eleven decisions, so nothing important is left implicit.
What we mark down — and why it matters.
| # | What we mark down | Why it matters |
|---|---|---|
| 1 | First-line therapy recommendation | The single best-supported treatment to start, with a confidence rationale. |
| 2 | Contraindications — what to avoid | Therapies this tumour will resist, so time and money are not wasted. |
| 3 | Biomarker-matched clinical trials | Recruiting studies that fit this exact molecular profile. |
| 4 | Biosimilar options | Clinically-equivalent, lower-cost alternatives available in India. |
| 5 | On-label vs off-label routes | Where a therapy is approved, and where it would be used off-label or via trial. |
| 6 | Resistance & monitoring plan | How the tumour may escape, and the serial testing to catch it. |
| 7 | Access, cost & reimbursement | Assistance programmes, schemes, and realistic out-of-pocket picture for India. |
| 8 | Hereditary / germline flags | Signals that inherited risk testing (Heritage) is warranted for you and relatives. |
| 9 | Pharmacogenomics & drug safety | How you may metabolise key drugs — to dose safely and avoid severe reactions. |
| 10 | Prognostic context | What the biology suggests about course, stated honestly and without false certainty. |
| 11 | Actionability Index & intelligence layers | A single readout of how targetable this tumour is, and the deeper computational analysis behind it. |
A full Blueprint Care report is a structured clinical document — not a printout.
It is organised into six groups that move from “what to do in the next 60 seconds” to the deepest biology.
The Chief Oncologist Summary
A one-page dashboard designed to give the treating doctor the critical decisions in under a minute: the Actionability Index, immediate directives (what to start, what to avoid), and urgent alerts (trial-ready status, hereditary-risk referral).
What separates Blueprint Care from a standard report is the analysis public annotation cannot provide.
The OnKommon Interpretation Engine applies six proprietary layers to every case.
CloneTrace™ — clonal architecture
Which mutations are founder (truncal) events present in every cancer cell, and which are later branches — so therapy targets the trunk, not a twig.
SynerGx™ — combination synergy
Which drug combinations offer real added benefit versus overlapping toxicity, scored as a net-benefit index.
PhenoMap™ — molecular subtype
The tumour's biological subtype, which sharpens both treatment choice and prognosis.
ImmunoLens™ — immune readiness
Whether the immune system can “see” the tumour — combining antigenicity with intact antigen-presentation — to predict immunotherapy response.
TrialGraph™ — trial & cohort matching
The recruiting trials that fit this profile, and a “patient-like-me” real-world response picture.
AccessMatch™ — access & economics
Biosimilars, assistance programmes, and the realistic cost pathway in India.
From consultation to continuous care.
Here is how it works.
Free Consultation
We understand your situation and choose the right starting test (or use your existing data).
Sample Collection
A simple blood draw, or your existing tissue block — collected by a qualified phlebotomist at home or in clinic.
Sequencing
An accredited laboratory reads the tumour's DNA with transparent quality control.
Interpretation Engine
The OnKommon Interpretation Engine annotates, matches, and applies the six intelligence layers.
KPCIRC sign-out
A molecular tumour board of licensed clinicians authors and signs the plan.
Your Report & Regional Summary
You receive the full report plus a plain-language version in your language.
Navigator Sessions
A dedicated navigator walks you and your family through results, access, and next steps.
Continue
Sentinel, Clear and Heritage extend the same care as your needs change.
Blood, tissue, or your existing data.
Blood (liquid biopsy)
A simple draw — no surgery, repeatable, ideal when tissue is hard to obtain. Choose the Signature blood tier that fits (STb, STb O, STb O+).
Tissue (FFPE)
If you have a tumour block, Signature STt O profiles it comprehensively.
Your existing data (Decipher)
Already tested elsewhere? Decipher builds the full Blueprint Care report from your existing results — no resequencing. Decipher Plus fills only the missing pieces.
Blueprint Care is a relationship, not a document.
- A dedicated navigator and in-person navigator sessions.
- Your report in your regional language, written for you and your family.
- A clear management timeline so you always know what is next.
- Genetic counselling through KPCIRC where hereditary risk is flagged.
- Financial navigation — biosimilars, assistance programmes, and schemes.
- Second opinions on demand, provided by KPCIRC on a paid basis.
What changes when you choose Blueprint Care.
| Standard report | Blueprint Care | |
|---|---|---|
| Output | Variant list | Ranked, signed decision + plan |
| Interpretation | Left to the reader | Six proprietary intelligence layers |
| Accountability | Often unclear | KPCIRC licensed sign-out |
| Trials & biosimilars | Rarely included | Matched and marked down |
| India cost pathway | Not addressed | Assistance programmes & schemes surfaced |
| Language | Technical English | Plus a regional-language summary |
| After the report | You are on your own | A navigator and continuous coordination |
Precision oncology is only real if you can access it.
Blueprint Care is designed around Indian access: we pair expensive targeted therapies with CDSCO-approved biosimilars where clinically equivalent, file the paperwork for Patient Assistance Programmes, and map state and private schemes — all coordinated by your navigator, and all explained in your language.
Blueprint Care — included with your test, not sold separately
Blueprint Care is not a standalone purchase. It is the decision report and the continuing clinical relationship that come with every Signature test or Decipher — the interpretation, the plan, and the care around it. Your consultation confirms which test feeds your Blueprint Care and the total.
Every report is authored and signed by KPCIRC's licensed molecular tumour board. Our technology informs; a clinician decides.
Need a second opinion or professional feedback? If you want an independent clinical view — or you are a clinician seeking a molecular tumour board discussion — our exclusive clinical partner KPCIRC provides paid second opinions, molecular tumour board reviews, and genetic counselling. Ask your navigator, or request it from any page.
A molecular tumour board (MTB) is a panel of specialists — medical oncologists, pathologists, geneticists and scientists — who review a patient's molecular results together and agree the best evidence-based options. At OnKommon, KPCIRC's MTB authors and signs every Blueprint Care decision, so a qualified human team — not software — stands behind the report.
The science behind this
Blueprint Care pairs comprehensive molecular profiling with a molecular tumour board (MTB). Both parts have been studied in thousands of patients.
Study 1 · A molecular tumour board improved outcomes
In 715 patients with advanced cancer, those whose therapy more closely matched their molecular profile on MTB advice achieved better response and longer survival than poorly matched patients.
Kato S, et al. Nature Communications, 2020.
Study 2 · Higher matching, better results (I-PREDICT)
In treatment-refractory cancers, patients whose therapy targeted more of their specific alterations (a higher matching score) had significantly longer progression-free and overall survival.
Sicklick JK, et al. Nature Medicine, 2019.
Study 3 · What the overall evidence shows
A systematic review concluded that molecular-tumour-board review appears to improve outcomes for people with cancer, while calling for more prospective randomized trials.
Systematic review, JCO Precision Oncology, 2021.
The words you will see, in plain language
Being clear about our limits
What we DO
- Turn comprehensive results into a ranked, signed treatment plan
- Match your profile to therapies, trials and biosimilars available in India
- Give you a named navigator and a summary in your regional language
- Provide serial monitoring (Sentinel, Clear) to follow the plan over time
What we DON'T do
- Diagnose cancer or prescribe medicines — your treating team does that
- Guarantee that a drug will be available, approved, covered, or effective
- Replace your oncologist or a molecular tumour board sign-out
- Act as an emergency service
Blueprint Care and the Signature tests that feed it is a genomic (DNA-based) test offered for use by qualified healthcare professionals. It is intended to support — not replace — clinical judgement, and must be interpreted alongside your full clinical history, other investigations, and applicable guidelines.
- • A result is not a diagnosis and does not by itself decide treatment.
- • A "not detected" or normal result does not rule out cancer or a genetic change.
- • Not all cancers release enough DNA into blood to be detected.
- • The test does not guarantee access to any medicine, its regulatory approval, insurance cover, or that a therapy will work.
- • Sample-collection kits are for use by qualified phlebotomists only — not for self-testing or self-sampling.
- • Confirmatory testing may be required.
Regulatory status (India). OnKommon's registration of its genomic tests as in-vitro diagnostic (IVD) medical devices with the Central Drugs Standard Control Organisation (CDSCO) is in progress (IVD class pending). Sequencing and variant calling are performed by an accredited laboratory partner (College of American Pathologists — CAP-accredited; ISO 15189) following international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and applicable Indian advertising standards.
Take the next step
Every OnKommon page offers three ways forward. Choose the one that fits where you are today.
Book a free Blueprint Consultation
A no-obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.
Book now →Free WhatsApp guidance (Signal)
A 4-hour triage reply to your first question, at no cost.
Start WhatsApp triage →